Literature DB >> 20811269

Is phonological-lexical representation preserved in moderate stage Alzheimer disease? Evidence from the efficacy of Korean syllabic cues.

Ji Hye Yoon1, Duk L Na, Juhee Chin, Hyun-Jung Ahn, Byung Hwa Lee, Mee Kyung Suh, Geon Ha Kim, Hyanghee Kim.   

Abstract

Patients with Alzheimer disease (AD) usually experience naming difficulty due to storage and access problems in phonological-lexical representation. Investigating naming response patterns followed by cueing may help us to understand the underlying mechanism of naming deficits in AD. A total of 221 patients with mild cognitive impairment and AD [Clinical Dementia Rating (CDR) 0.5, 1, 2] were included as subjects. Sixty items of the Korean version of the Boston Naming Test were given, and upon failure, semantic/syllabic cues were verbally presented. From the results, even in the CDR 2 group, which is considered to be a moderate stage of AD, syllabic cues significantly facilitated correct responses. Our findings are in contrast with previous studies conducted with English-speaking patients, which reported that phonological-lexical representation may have been disrupted in the moderate stage of AD, and that none of the cues facilitated correct word retrieval. The difference may be ascribed to the fact that direct access to the phonological-lexical representation via syllabic cues was possible in the confrontation naming task performed by the Korean patients. It can be concluded that phonological-lexical representation in moderate stage Korean AD might be partially preserved because syllabic cues in AD patients were effective in facilitating target words.

Entities:  

Mesh:

Year:  2010        PMID: 20811269     DOI: 10.1097/WAD.0b013e3181eb2f53

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  1 in total

1.  The tip-of-the-tongue phenomenon in older adults with subjective memory complaints.

Authors:  JungWan Kim; Minyoung Kim; Ji Hye Yoon
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.